Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Gossamer Bio, Inc.NASDAQ: GOSS

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns positive

Q1 FY2026 change in working capital was $1.81M, compared with -$3.41M a year earlier. Trailing-twelve-month change in working capital was -$8.41M. Over 3 fiscal years it compounded at +45.1% a year.

Context

  • Change in working capital amounted to 28.1% of revenue in FY2025, down 6.3 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near $1.81M or moves back toward the trailing-twelve-month quarterly average of -$2.1M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.81M+153.9% QoQ
Last fiscal yearDec 2025
-$13.63M-134.5% YoY
LTMMar 2026
-$8.41M-116.6% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+153.2%——
1 year-134.5%——
3-year CAGR+45.1%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(13.63M) USD
Year-over-year change
-134.5%

Change in Working Capital vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 change in working capital of $8.41M is the 6th largest of the 9 companies compared; the peer median is $6.72M.
  • Its year-over-year change of -116.6% is the 6th highest of 8, against a peer median of -10.5%.
  • Change in working capital amounts to 15.1% of revenue for GOSS, versus a peer median of 11.2%.
GOSS Competitors Peer median
Change in Working Capital for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$24.07M -472.0%—34.6%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$22.34M ——19.3%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.86M +244.6%-2.8%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.38M -10.5%-12.4%4.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$8.59M +375.9%—9.7%
GOSSGossamer Bio, Inc.LTM Mar 2026$8.41M -116.6%+45.1%15.1%
PRTAProthena Corporation plcLTM Mar 2026$7.3M -87.4%-39.5%12.6%
RGNXREGENXBIO Inc.LTM Mar 2026$6.13M -120.4%-5.5%7.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.48M +328.3%+36.3%—
Peer median (excluding GOSS) $6.72M-10.5%-5.5%11.2%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
Deferred Income Tax00000
Stock-Based Compensation32.01M42.55M28.52M20.62M10.56M
Change in Working Capital774K(4.46M)(14.84M)39.46M(13.63M)
Accounts Receivables000(5.34M)(6.89M)
Inventory00000
Accounts Payables(4.43M)(1.81M)3.99M(1.66M)(2.75M)
Other Working Capital5.2M(2.65M)(18.83M)46.45M(3.99M)
Other Non-Cash Items7.17M(177K)2.6M(11.17M)1.18M
Operating Cash Flow(188.89M)(187.03M)(159.16M)(3.47M)(171.27M)
Capital Expenditures(1.62M)(475K)00(79K)
Acquisitions (Net)0(65K)000
Purchases of Investments(152.03M)(238.06M)(441.67M)(494.78M)(227.11M)
Sales of Investments36.23M237.5M330.7M523.8M383.54M
Other Investing Activities(75K)65K000
Investing Cash Flow(117.43M)(1.04M)(110.97M)29.02M156.36M
Debt Repayment0(5.81M)(11.61M)(12.58M)0
Common Stock Issued0119.95M201.32M464K6.43M
Common Stock Repurchased000629K0
Dividends Paid00000
Other Financing Activities3.33M2.95M444K00
Financing Cash Flow3.33M117.09M190.15M(11.49M)6.43M
Effect of Forex Changes(165K)(517K)110K(102K)141K
Net Change in Cash(303.15M)(71.49M)(79.86M)13.97M(8.34M)
Free Cash Flow(190.51M)(187.51M)(159.16M)(3.47M)(171.35M)

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.